Skip to main content
. 2022 Sep 8;16:984494. doi: 10.3389/fnbeh.2022.984494

Figure 3.

Figure 3

Systemic aromatase inhibition decreases hippocampal, ELISA-measured estradiol-immunoreactivity but estradiol was not detected by mass spectrometry. (A) Estradiol-immunoreactivity in the hippocampus (pg/g of hippocampus wet weight) as measured by estradiol ELISA. Letrozole reduces hippocampal estrogen. Estradiol in proestrus female hippocampus is lower than estradiol in male or estrous female hippocampus (n = 3–13/group). (B) The number of ions in the measured peaks (m/z 271.17) normalized to g of the hippocampus. Again, concentration in proestrus female hippocampus is lower than in male or estrous female hippocampus (n = 2–7/group). (C) The m/z 271.17 peak in hippocampus samples elute at 2.24 min while a 17β-Estradiol standard elutes at 2.47 min, indicating that these peaks are not 17β-Estradiol. (D) MS/MS spectrum of the [M-H]- ion (m/z 271.1704) for a 1:1 mixture of deuterated-labeled and unlabeled estradiol standards. (E) MS/MS spectrum of the [M-H]- ion (m/z 271.1704) for an unknown compound identified in a male hippocampus. Post test p-values are provided above the corresponding comparisons. Individual points represent individual mice. Data are presented as mean ± SEM.